NCT03624751

Brief Summary

The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
107

participants targeted

Target at P50-P75 for all trials

Timeline
51mo left

Started Jun 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress66%
Jun 2018Jun 2030

First Submitted

Initial submission to the registry

May 24, 2018

Completed
13 days until next milestone

Study Start

First participant enrolled

June 6, 2018

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 10, 2018

Completed
9.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2028

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2030

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

10.1 years

First QC Date

May 24, 2018

Last Update Submit

April 27, 2026

Conditions

Thyroid Cancer

Outcome Measures

Primary Outcomes (1)

  • Zung's Self-reported depression scale

    Depression symtpoms

    1 month

Secondary Outcomes (7)

  • Brain-derived neurotrophic factor

    1 month

  • orexin

    1 month

  • Body composition

    1 months

  • VCAM-1

    1 months

  • CRP

    1 months

  • +2 more secondary outcomes

Interventions

radioiodineRADIATION

Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with diagnosis of thyroid cancer

You may qualify if:

  • Patients with diagnosis of thyroid cancer。
  • Patients who need radioiodine therapy or scan。

You may not qualify if:

  • Patients cannot cooperate with blood test.。
  • Patients cannot cooperate with radioiodine therapy。

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Division of Endocrinology and Metabolism in Taichung Veterans General Hospital

Taichung, 407, Taiwan

Location

MeSH Terms

Conditions

Thyroid Neoplasms

Interventions

Iodine-131

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2018

First Posted

August 10, 2018

Study Start

June 6, 2018

Primary Completion (Estimated)

June 30, 2028

Study Completion (Estimated)

June 30, 2030

Last Updated

May 1, 2026

Record last verified: 2026-04

Locations

TW(1)